Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

Cephalalgia

Volumn 34, Issue 12, 2014, Pages 986-993

  Goadsby, P J ^a,b   Grosberg, B M ^c   Mauskop, A ^d   Cady, R ^e   Simmons, K A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d New York Headache Center   (United States)

^e HEADACHE CARE CENTER   (United States)

^f ElectroCore LLC   (United States)

Author keywords

acute treatment; Migraine; neuromodulation; vagus nerve

Indexed keywords

ADULT; ANALGESIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEVICE SAFETY; DISABILITY; DIZZINESS; FATIGUE; FEMALE; FEVER; HUMAN; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MUSCLE SPASM; MUSCLE TWITCH; NAUSEA; NERVE STIMULATOR; OPEN STUDY; PAIN SEVERITY; PATIENT SAFETY; PHONOPHOBIA; PHOTOPHOBIA; PILOT STUDY; PLACEBO EFFECT; POLLAKISURIA; SELF EVALUATION; SHOULDER PAIN; SINUS HEADACHE; SKIN REDNESS; SKIN STIMULATION; SNEEZING; STIFF NECK; TINNITUS; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; VOICE CHANGE; VOICE DISORDER; CLINICAL TRIAL; MIGRAINE DISORDERS; MULTICENTER STUDY;

ADULT; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PILOT PROJECTS; VAGUS NERVE STIMULATION;

EID: 84908206786     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414524494     Document Type: Article

References (49)

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2197-2223
2. Bigal ME, Rapoport AM, Tepper SJ, et al. The classification of chronic daily headache in adolescents-a comparison between the second edition of the International Classification of Headache Disorders and alternative diagnostic criteria. Headache. 2005; 45: 582-589
3. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012; 19: 155-162
4. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002; 346: 257-270
5. Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584
6. Lance JW, Goadsby PJ Mechanism and Management of Headache. 7 th edn. New York: Elsevier, 2005. New York: Elsevier; 2005:
7. Goadsby PJ. The pharmacology of headache. Progr Neurobiol. 2000; 62: 509-525
8. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675
9. Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004; 44: 414-425
10. Sadler RM, Purdy RA, Rahey S. Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia. 2002; 22: 482-484
11. Goadsby PJ, Grosberg BM, Mauskop A, et al. Non-invasive vagus nerve stimulation (nVNS) for acute treatment of migraine: An open-label pilot study. Neurology. 2013;: S40.004-S40.004
12. The International Classification of Headache Disorders. Cephalalgia. 2004; 24: 1-160
13. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991; 31: 295-299
14. Lipton RB, Stewart WF, Cady R, et al. Sumatriptan for the range of headaches in migraine sufferers: Results of the Spectrum Study. Headache. 2000; 40: 783-791
15. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658
16. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind placebo-controlled trial of almotriptan. Cephalalgia. 2008; 28: 383-391
17. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123
18. Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012; 11: 405-413
19. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012; 32: 6-38
20. Goldstein H Multilevel statistical models. 4 th edn. London: John Wiley & Sons, 2011. London: John Wiley & Sons; 2011:
21. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical Principles for Clinical Trials. In: European Medicines Agency Geneva: International conference on harmonisation, 1998.
22. Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia. 2005; 25: 82-86
23. Hord ED, Evans MS, Mueed S, et al. The effect of vagus nerve stimulation on migraines. J Pain. 2003; 4: 530-534
24. Lenaerts ME, Oommen KJ, Couch JR, et al. Can vagus nerve stimulation help migraine?. Cephalalgia. 2008; 28: 392-395
25. Cecchini AP, Mea E, Tullo V, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: Preliminary data. Neurol Sci. 2009; 30: S101-S104
26. Kirchner A, Birklein F, Stefan H, et al. Left vagus nerve stimulation suppresses experimentally induced pain. Neurology. 2000; 55: 1167-1171
27. Nesbitt AD, Marin JCA, Tomkins E, et al. Non-invasive vagus nerve stimulation for the treatment of cluster headache: A cohort study. Cephalalgia. 2013; 33: 107-107
28. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007; 297: 1443-1454
29. Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006; 26: 537-547
30. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010; 30: 1336-1345
31. Diener HC, Dodick DW, Goadsby PJ, et al. Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia. 2008; 28: 35-40
32. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991; 325: 316-321
33. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9: 373-380
34. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: Results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache. 2007; 47: 189-198
35. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: Results from the rizatriptan TAME studies. Cephalalgia. 2007; 27: 1055-1060
36. Gray H Anatomy of the human body (www.bartleby.com/107/). Philadelphia, PA: Lea & Febiger; 1918:
37. Kaube H, Keay KA, Hoskin KL, et al. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 1993; 629: 95-102
38. Foley JO, DuBois FS. Quantitative studies of the vagus nerve in the cat. J Comp Neurol. 1937; 67: 49-67
39. Agostoni E, Chinnock JE, De Daly MB, et al. Functional and histological studies of the vagus nerve and its branches to the heart, lungs and abdominal viscera in the cat. J Physiol. 1957; 135: 182-205
40. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology. 1960; 10: 555-563
41. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: A c-fos immunocytochemical study. J Anat. 1997; 190: 367-375
42. Hoffmann TJ, Simon BJ, Zhang Y, et al. Low voltage vagal nerve stimulation reduces bronchoconstriction in guinea pigs through catecholamine release. Neuromodulation. 2012; 15: 527-536
43. Hoffmann TJ, Mendez S, Staats P, et al. Inhibition of histamine-induced bronchoconstriction in guinea pig and swine by pulsed electrical vagus nerve stimulation. Neuromodulation. 2009; 12: 261-269
44. Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012; 52: 1402-1410
45. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache. 2011; 51: 507-517
46. Djupesland PG, Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia. 2010; 30: 933-942
47. Cady R, Messina J, Carothers J, et al. Efficacy and safety of a novel Breath-Powered™ powder sumatriptan intranasal treatment for acute migraine. Cephalalgia. 2013; 33: 21-22
48. Peikert A, Becker WJ, Ashford EA, et al. Sumatriptan nasal spray: A dose-ranging study in the acute treatment of migraine. Eur J Neurol. 1999; 6: 43-49
49. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003; 17: 653-667